$BDSX
BIODESIX INC

2024 Q3 Form 10-Q Financial Statement

#000095017024092773 Filed on August 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $18.15M $17.93M
YoY Change 34.54% 50.99%
Cost Of Revenue $4.179M $3.877M
YoY Change 29.38% 19.73%
Gross Profit $13.97M $14.05M
YoY Change 36.18% 62.71%
Gross Profit Margin 76.98% 78.37%
Selling, General & Admin $20.02M $19.66M
YoY Change 29.17% 18.07%
% of Gross Profit 143.26% 139.95%
Research & Development $2.547M $2.558M
YoY Change 31.42% -12.1%
% of Gross Profit 18.23% 18.21%
Depreciation & Amortization $1.000M $900.0K
YoY Change 233.33% 200.0%
% of Gross Profit 7.16% 6.41%
Operating Expenses $26.74M $26.16M
YoY Change 29.42% 14.75%
Operating Profit -$8.591M -$8.237M
YoY Change 19.79% -24.62%
Interest Expense -$2.041M $1.936M
YoY Change -185.54% -20.33%
% of Operating Profit
Other Income/Expense, Net -$1.667M -$2.571M
YoY Change -55.86% 5.85%
Pretax Income -$10.26M -$10.81M
YoY Change -6.32% -19.08%
Income Tax
% Of Pretax Income
Net Earnings -$10.26M -$10.81M
YoY Change -6.31% -19.08%
Net Earnings / Revenue -56.51% -60.3%
Basic Earnings Per Share -$0.07 -$0.08
Diluted Earnings Per Share -$0.07 -$0.08
COMMON SHARES
Basic Shares Outstanding 145.2M 114.7M
Diluted Shares Outstanding 146.3M 127.2M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $31.41M $42.22M
YoY Change 58.62% 142.51%
Cash & Equivalents $31.41M $42.22M
Short-Term Investments
Other Short-Term Assets $4.575M $5.232M
YoY Change 39.99% 40.76%
Inventory
Prepaid Expenses
Receivables $8.036M $10.13M
Other Receivables $0.00 $0.00
Total Short-Term Assets $44.02M $57.58M
YoY Change 52.38% 128.08%
LONG-TERM ASSETS
Property, Plant & Equipment $28.68M $28.02M
YoY Change 12.95% 47.5%
Goodwill $15.03M $15.03M
YoY Change 0.0% 0.0%
Intangibles $6.438M $6.884M
YoY Change -23.5% -22.4%
Long-Term Investments
YoY Change
Other Assets $6.656M $6.561M
YoY Change -4.44% -6.11%
Total Long-Term Assets $58.73M $58.26M
YoY Change 1.43% 11.23%
TOTAL ASSETS
Total Short-Term Assets $44.02M $57.58M
Total Long-Term Assets $58.73M $58.26M
Total Assets $102.7M $115.8M
YoY Change 18.39% 49.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.537M $2.220M
YoY Change -12.64% -36.59%
Accrued Expenses $8.553M $8.324M
YoY Change 23.14% 19.24%
Deferred Revenue $700.0K $400.0K
YoY Change 0.0% -63.64%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $29.00K $37.00K
YoY Change -71.0% -26.0%
Total Short-Term Liabilities $12.96M $17.55M
YoY Change -60.3% -37.2%
LONG-TERM LIABILITIES
Long-Term Debt $36.11M $35.81M
YoY Change 44.45% 45.21%
Other Long-Term Liabilities $620.0K $744.0K
YoY Change -23.93% -16.96%
Total Long-Term Liabilities $61.92M $62.03M
YoY Change 11.41% 9.47%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.96M $17.55M
Total Long-Term Liabilities $61.92M $62.03M
Total Liabilities $74.89M $79.58M
YoY Change -15.13% -5.95%
SHAREHOLDERS EQUITY
Retained Earnings -$454.2M -$444.0M
YoY Change 10.68% 11.14%
Common Stock $145.0K $145.0K
YoY Change 64.77% 83.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $27.86M $36.26M
YoY Change
Total Liabilities & Shareholders Equity $102.7M $115.8M
YoY Change 18.39% 49.24%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$10.26M -$10.81M
YoY Change -6.31% -19.08%
Depreciation, Depletion And Amortization $1.000M $900.0K
YoY Change 233.33% 200.0%
Cash From Operating Activities -$10.67M -$18.57M
YoY Change 177.89% -2081.96%
INVESTING ACTIVITIES
Capital Expenditures $286.0K $1.997M
YoY Change -95.14% -69.14%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$286.0K -$1.997M
YoY Change -95.14% -69.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 144.0K 51.30M
YoY Change -98.81% -2301.55%
NET CHANGE
Cash From Operating Activities -10.67M -18.57M
Cash From Investing Activities -286.0K -1.997M
Cash From Financing Activities 144.0K 51.30M
Net Change In Cash -10.81M 30.73M
YoY Change -544.98% -490.69%
FREE CASH FLOW
Cash From Operating Activities -$10.67M -$18.57M
Capital Expenditures $286.0K $1.997M
Free Cash Flow -$10.96M -$20.57M
YoY Change 12.73% 271.6%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001439725
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q2 us-gaap Restricted Cash Current Asset Statement Of Financial Position Extensible List
RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsCurrent
CY2023Q4 us-gaap Restricted Cash Current Asset Statement Of Financial Position Extensible List
RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsCurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39659
dei Entity Registrant Name
EntityRegistrantName
BIODESIX, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-3986492
dei Entity Address Address Line1
EntityAddressAddressLine1
919 West Dillon Rd
dei Entity Address City Or Town
EntityAddressCityOrTown
Louisville
dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80027
dei City Area Code
CityAreaCode
303
dei Local Phone Number
LocalPhoneNumber
417-0500
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
BDSX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
145177125
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42219000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26284000
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
238000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
65000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10128000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7679000
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
5232000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5720000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
57579000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
39683000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28019000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27867000
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6884000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7911000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1767000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1745000
CY2024Q2 us-gaap Goodwill
Goodwill
15031000
CY2023Q4 us-gaap Goodwill
Goodwill
15031000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6561000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6859000
CY2024Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
58262000
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
59413000
CY2024Q2 us-gaap Assets
Assets
115841000
CY2023Q4 us-gaap Assets
Assets
99096000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2220000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2929000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8324000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7710000
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
447000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
324000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
300000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
252000
CY2024Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
5838000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
21857000
CY2024Q2 us-gaap Notes Payable To Bank Current
NotesPayableToBankCurrent
37000
CY2023Q4 us-gaap Notes Payable To Bank Current
NotesPayableToBankCurrent
51000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
386000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
293000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
17552000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
33416000
CY2024Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
35807000
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
35225000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25478000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25163000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
744000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
712000
CY2024Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
62029000
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
61100000
CY2024Q2 us-gaap Liabilities
Liabilities
79581000
CY2023Q4 us-gaap Liabilities
Liabilities
94516000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
145149630
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
145149630
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
96235883
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
96235883
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
145000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
96000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
480103000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
424050000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-443988000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-419566000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
36260000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
4580000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
115841000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
99096000
CY2024Q2 us-gaap Revenues
Revenues
17925000
CY2023Q2 us-gaap Revenues
Revenues
11872000
us-gaap Revenues
Revenues
32743000
us-gaap Revenues
Revenues
20928000
CY2024Q2 bdsx Direct Costs And Expenses
DirectCostsAndExpenses
3877000
CY2023Q2 bdsx Direct Costs And Expenses
DirectCostsAndExpenses
3238000
bdsx Direct Costs And Expenses
DirectCostsAndExpenses
7052000
bdsx Direct Costs And Expenses
DirectCostsAndExpenses
6407000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2558000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2910000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4598000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6161000
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
19660000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
16651000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
40216000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
35640000
CY2024Q2 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
67000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
135000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
20000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
26162000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
22799000
us-gaap Operating Expenses
OperatingExpenses
52001000
us-gaap Operating Expenses
OperatingExpenses
48228000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8237000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10927000
us-gaap Operating Income Loss
OperatingIncomeLoss
-19258000
us-gaap Operating Income Loss
OperatingIncomeLoss
-27300000
CY2024Q2 us-gaap Interest Expense
InterestExpense
1936000
CY2023Q2 us-gaap Interest Expense
InterestExpense
2430000
us-gaap Interest Expense
InterestExpense
4465000
us-gaap Interest Expense
InterestExpense
4821000
CY2024Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-248000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-248000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-61000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-387000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-451000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2571000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2429000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5164000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4758000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-10808000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-13356000
us-gaap Net Income Loss
NetIncomeLoss
-24422000
us-gaap Net Income Loss
NetIncomeLoss
-32058000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
127168000
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
127168000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78506000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78506000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112167000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
112167000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78138000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78138000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
4580000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
607000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
282000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2640000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-13614000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-5502000
CY2024Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
33150000
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
18198000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1218000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-10808000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
36260000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
20606000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-61000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
420000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2281000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-18702000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
4550000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
81000
CY2023Q2 bdsx Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Optionsvested In Period Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount
1000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
674000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1057000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-13356000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-6993000
us-gaap Profit Loss
ProfitLoss
-24422000
us-gaap Profit Loss
ProfitLoss
-32058000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2832000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1569000
bdsx Operating Lease Right Of Use Asset Accretion Amortization Expense
OperatingLeaseRightOfUseAssetAccretionAmortizationExpense
-191000
bdsx Operating Lease Right Of Use Asset Accretion Amortization Expense
OperatingLeaseRightOfUseAssetAccretionAmortizationExpense
1394000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-248000
us-gaap Share Based Compensation
ShareBasedCompensation
3858000
us-gaap Share Based Compensation
ShareBasedCompensation
3338000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-61000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
220000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
367000
bdsx Accrued Interest Amortization Of Debt Issuance Costs And Other
AccruedInterestAmortizationOfDebtIssuanceCostsAndOther
2084000
bdsx Accrued Interest Amortization Of Debt Issuance Costs And Other
AccruedInterestAmortizationOfDebtIssuanceCostsAndOther
2695000
us-gaap Inventory Write Down
InventoryWriteDown
12000
us-gaap Inventory Write Down
InventoryWriteDown
115000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
135000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
20000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2669000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-580000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-1129000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-1349000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-12000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-679000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1236000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
71000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
49000
bdsx Increase Decrease In Contingent Consideration
IncreaseDecreaseInContingentConsideration
-17167000
bdsx Tenant Improvement Allowances Received
TenantImprovementAllowancesReceived
12978000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
645000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-320000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33882000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6749000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2160000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14093000
bdsx Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net
PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet
110000
bdsx Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net
PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet
85000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2270000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14178000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
55625000
bdsx Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
282000
bdsx Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
420000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
87000
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
4262000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
25000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
24000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
37000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
832000
bdsx Payment Of Equity Financing Costs
PaymentOfEquityFinancingCosts
3615000
bdsx Payment Of Equity Financing Costs
PaymentOfEquityFinancingCosts
61000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-150000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-79000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
52087000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4751000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15935000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-25678000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26371000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43174000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42306000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17496000
bdsx Debt Issuance Costs Included In Accounts Payable And Other Accrued Liabilities
DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities
2000
bdsx Equity Financing Costs Included In Accounts Payable And Other Accrued Liabilities
EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities
55000
bdsx Issuance Of Perceptive Warrants
IssuanceOfPerceptiveWarrants
674000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
281000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
858000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
326000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
773000
us-gaap Interest Paid Net
InterestPaidNet
2472000
us-gaap Interest Paid Net
InterestPaidNet
2119000
bdsx Purchases Of Property Equipment Included In Accounts Payable And Accrued Liabilities
PurchasesOfPropertyEquipmentIncludedInAccountsPayableAndAccruedLiabilities
68000
bdsx Purchases Of Property Equipment Included In Accounts Payable And Accrued Liabilities
PurchasesOfPropertyEquipmentIncludedInAccountsPayableAndAccruedLiabilities
27000
bdsx Number Of Cancer Test
NumberOfCancerTest
5
bdsx Number Of Commercial Blood Based Test
NumberOfCommercialBloodBasedTest
2
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the balance sheet date and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Other Uncertainties</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Substantially all of the Company’s cash and cash equivalents are deposited with one major financial institution in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institution with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating and money market accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Several of the components for certain of the Company's sample collection kits, test reagents, and test systems are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, the Company could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For a discussion of credit risk concentration of accounts receivable as of June 30, 2024 and December 31, 2023, see Note 9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> – Revenue and Accounts Receivable Credit Concentration</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2024Q2 us-gaap Restricted Cash
RestrictedCash
100000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
100000
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
100000
CY2024Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
100000
us-gaap Inventory Write Down
InventoryWriteDown
100000
CY2024Q2 bdsx Number Of Milestone Payments Remaining
NumberOfMilestonePaymentsRemaining
1
CY2024Q2 bdsx Milestone Payment Remaining Amount
MilestonePaymentRemainingAmount
6100000
CY2024Q2 bdsx Milestone Payment Expiration Date
MilestonePaymentExpirationDate
2024-10-01
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
35277000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
33479000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7258000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5612000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28019000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27867000
CY2024Q2 us-gaap Depreciation
Depreciation
900000
us-gaap Depreciation
Depreciation
1800000
CY2023Q2 us-gaap Depreciation
Depreciation
300000
us-gaap Depreciation
Depreciation
600000
CY2024Q2 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
18962000
CY2024Q2 bdsx Intangible Assets Accumulated Amortization Excluding Goodwill
IntangibleAssetsAccumulatedAmortizationExcludingGoodwill
12078000
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6884000
CY2023Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
18991000
CY2023Q4 bdsx Intangible Assets Accumulated Amortization Excluding Goodwill
IntangibleAssetsAccumulatedAmortizationExcludingGoodwill
11080000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7911000
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
500000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
500000
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1000000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1000000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
1006000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
2009000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1990000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1031000
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
83000
CY2024Q2 bdsx Finite Lived Intangible Assets Amortization Expense Year Five And Thereafter
FiniteLivedIntangibleAssetsAmortizationExpenseYearFiveAndThereafter
648000
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
6767000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4648000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3855000
CY2024Q2 bdsx Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
1044000
CY2023Q4 bdsx Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
983000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2632000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2872000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8324000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7710000
CY2024Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
4209000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
4802000
CY2024Q2 us-gaap Notes Payable
NotesPayable
35844000
CY2023Q4 us-gaap Notes Payable
NotesPayable
35276000
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
37000
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
51000
CY2024Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
35807000
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
35225000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
25000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
21000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
7000
CY2024Q2 bdsx Long Term Debt Maturities Repayments Of Principal In Year Three And Thereafter
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThreeAndThereafter
40000000
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
40053000
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
600000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
1100000
us-gaap Operating Lease Expense
OperatingLeaseExpense
2200000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y6M
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.114
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1392000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3908000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4171000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4063000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
4151000
CY2024Q2 bdsx Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
28113000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
45798000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
20020000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
25778000
CY2024Q2 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2028-02-23
bdsx Primary Sources Of Revenue Description
PrimarySourcesOfRevenueDescription
We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic Tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. We also recognize revenue from other services, including amounts derived from licensing our technologies (Biopharmaceutical Services and other).
CY2024Q2 us-gaap Revenues
Revenues
17925000
CY2023Q2 us-gaap Revenues
Revenues
11872000
us-gaap Revenues
Revenues
32743000
us-gaap Revenues
Revenues
20928000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
300000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
300000
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
400000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
792858
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1218000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1057000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3858000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3338000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2041000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.36
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
964000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2138000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.67
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
132000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
2.16
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
14000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.53
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4033000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.51
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
737000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1525000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.71
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y1M6D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
566000
bdsx Description Of Offering Period Under Plan
DescriptionOfOfferingPeriodUnderPlan
ESPP provides for successive six-month offering periods beginning on September 1st and March 1st of each year.
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
216506
CY2024Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
430612
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-10808000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-13356000
us-gaap Net Income Loss
NetIncomeLoss
-24422000
us-gaap Net Income Loss
NetIncomeLoss
-32058000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
127168000
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
127168000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78506000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78506000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112167000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
112167000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78138000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78138000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14944000
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12564000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14944000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12564000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q2 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2023Q2 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
bdsx Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-092773-index-headers.html Edgar Link pending
0000950170-24-092773-index.html Edgar Link pending
0000950170-24-092773.txt Edgar Link pending
0000950170-24-092773-xbrl.zip Edgar Link pending
bdsx-20240630.htm Edgar Link pending
bdsx-20240630.xsd Edgar Link pending
bdsx-ex10_1.htm Edgar Link pending
bdsx-ex31_1.htm Edgar Link pending
bdsx-ex31_2.htm Edgar Link pending
bdsx-ex32_1.htm Edgar Link pending
bdsx-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
bdsx-20240630_htm.xml Edgar Link completed
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending